Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.44 |
| ▸ | PRKCG | P05129 | 3/20 | 0.44 |
| ▸ | PRKCB | P05771 | 3/20 | 0.44 |
| ▸ | PRKCA | P17252 | 3/20 | 0.44 |
| ▸ | PRKCH | P24723 | 3/20 | 0.44 |
| ▸ | PRKCI | P41743 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276527 | 0.83 | TNF (0.53) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL6240424 | 0.77 | LMNA (0.63) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL275571 | 0.77 | KDM4E (0.42) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL6968741 | 0.77 | KDM4E (0.57) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL7948611 | 0.76 | KDM4E (0.61) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL7231935 | 0.75 | LMNA (0.50) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL17040876 | 0.75 | KDM4E (0.55) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL276518 | 0.74 | KDM4E (1.00) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL3805113 | 0.74 | CYP1A2 (0.59) | CYP3A4LMNACYP2D6KDM4ECYP1A2 | |
| SCHEMBL9746543 | 0.74 | KDM4E (0.53) | CYP3A4LMNACYP2D6KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | claimed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | claimed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-RE43098-E1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | claimed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | claimed |
| EP-2277877-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-26 | — | — | EP | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | claimed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | claimed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | claimed |
| EP-1330444-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| EP-1315715-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| EP-1309568-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1309569-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002036587-A2 | PROCESS FOR THE PRODUCTION OF 4-QUINAZOLINYLPIPERAZIN-1-CARBOXYLIC ACID PHENYLAMIDES | COR THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | NME1, NME2, TNNI3K | CYP3A4 1397/4885LMNA 2087/4885CYP2D6 1695/4885 |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | CYP3A4 4346/4885LMNA 4350/4885CYP2D6 3498/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | CYP3A4 4346/4885LMNA 4350/4885CYP2D6 3498/4885 |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | CYP3A4 4683/4885LMNA 3668/4885CYP2D6 3755/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | CYP3A4 4346/4885LMNA 4350/4885CYP2D6 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.